Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Breast Cancer
PROCEDURE: Tumor Sample|PROCEDURE: Serum Sample
To correlate tumor gene expression (genomic profile) with response to lonafarnib in patients with advanced breast cancer, 24 months
To correlate serum and tumor proteomic profiles with response to lonafarnib, 24 months|To compare serum and tissue proteomic analyses, 24 months|To compare genomic and proteomic profiles, 24 months|To correlate toxicity and /or response with drug-specific pharmacogenomic parameters, 24 months
OUTLINE: This is a multi-center study.

Sample Collection:

* Tumor sample
* Serum sample

Treatment Regimen:

* All registered patients must be planning treatment with lonafarnib